Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
| العنوان: | Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials |
|---|---|
| المؤلفون: | Geuna, E, Roda, D, Rafii, S, Jimenez, B, Capelan, M, Rihawi, K, Montemurro, F, Yap, T A, Kaye, S B, De Bono, J S, Molife, L R, Banerji, U |
| المصدر: | British Journal of Cancer |
| بيانات النشر: | Nature Publishing Group, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, mTOR inhibitors, Adolescent, Antineoplastic Agents, Severity of Illness Index, Young Adult, Risk Factors, Neoplasms, Hyperglycaemia, Humans, Hypoglycemic Agents, Protein Kinase Inhibitors, Aged, Phosphoinositide-3 Kinase Inhibitors, Retrospective Studies, Aged, 80 and over, Clinical Trials, Phase I as Topic, metabolic complications, TOR Serine-Threonine Kinases, AKT inhibitors, PI3K inhibitors, Middle Aged, Case-Control Studies, Hyperglycemia, Clinical Study, PI3K–AKT–mTOR pathway, Female, Proto-Oncogene Proteins c-akt, Signal Transduction |
| الوصف: | Background: PI3K–AKT–mTOR inhibitors (PAMi) are promising anticancer treatments. Hyperglycaemia is a mechanism-based toxicity of these agents and is becoming increasingly important with their use in larger numbers of patients. Methods: Retrospective case-control study comparing incidence and severity of hyperglycaemia (all grades) between a case group of 387 patients treated on 18 phase I clinical trials with PAMi (78 patients with PI3Ki, 138 with mTORi, 144 with AKTi and 27 with PI3K/mTORi) and a control group of 109 patients treated on 10 phase I clinical trials with agents not directly targeting the PAM pathway. Diabetic patients were excluded in both groups. Results: The incidence of hyperglycaemia was not significantly different between cases and controls (86.6% vs 80.7%, respectively, P=0.129). However, high grade (grade 3–4) hyperglycaemia was more frequent in the PAMi group than in controls (6.7% vs 0%, respectively, P=0.005). The incidence of grade 3–4 hyperglycaemia was greater with AKT and multikinase inhibitors compared with other PAMi (P |
| اللغة: | English |
| تدمد: | 1532-1827 0007-0920 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=pmid________::fae21ccd41a8d0c04c35fbb9721a2e35Test http://europepmc.org/articles/PMC4705886Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.pmid..........fae21ccd41a8d0c04c35fbb9721a2e35 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15321827 00070920 |
|---|